Dose-response relationships for alendronate treatment in osteoporotic elderly women. Alendronate Elderly Osteoporosis Study Centers
about
Giant osteoclast formation and long-term oral bisphosphonate therapyGiant osteoclasts after long-term bisphosphonate therapy: diagnostic challengesReduced osteoclastogenesis and RANKL expression in marrow from women taking alendronate.A higher dosage of oral alendronate will increase the subsequent cancer risk of osteoporosis patients in Taiwan: a population-based cohort studyPromotion of osteoclast survival and antagonism of bisphosphonate-induced osteoclast apoptosis by glucocorticoids.Effects of D-003 (10 mg/day) on bone mineral density of the lumbar spine and femoral neck in postmenopausal women: a randomized, double-blinded study.Medical treatment of vertebral osteoporosisOsteoporosis: the emperor has no clothesThe association between blood lead levels and osteoporosis among adults--results from the third national health and nutrition examination survey (NHANES III).Alendronate sodium in the management of osteoporosis.Utilization of DXA Bone Mineral Densitometry in Ontario: An Evidence-Based AnalysisAlendronate for osteoporosis. Safe and efficacious nonhormonal therapyOral bisphosphonates may not decrease hip fracture risk in elderly Spanish women: a nested case-control study.Histomorphometric assessment of the long-term effects of alendronate on bone quality and remodeling in patients with osteoporosis.Bazedoxifene versus oral bisphosphonates for the prevention of nonvertebral fractures in postmenopausal women with osteoporosis at higher risk of fracture: a network meta-analysis.The efficacy and safety of vertebral fracture prevention therapies in post-menopausal osteoporosis treatment: Which therapies work best? a network meta-analysis.
P2860
Q24626459-B42E6101-F40C-4B0C-B582-AFB80423BE44Q33814312-4258388E-D11B-4A7C-91AD-CB4D442E2478Q33822541-65008F56-DB49-46DC-B0B8-83DB7CEF6E45Q34541581-D51C374C-08F4-4E3B-81B3-95FBFBE3398DQ34790932-D352263A-3295-45C4-B641-15EAE75C4662Q35033570-288E26DA-668C-4B6E-8E48-EAAB02EE469DQ35299212-33F92F1B-1432-480E-B2B9-62FAFFF28703Q35835844-29D73625-1725-4F3A-95E1-3FCE23000941Q35879796-6B803D2A-581A-44FD-AB0F-0325F91689CFQ35919111-522DAC24-B27C-4160-9384-1F92D8EDDFAEQ36045845-77EB1A84-86D2-4F8E-B653-140161D98B8DQ36514830-DC8506FA-7DBC-406C-9E09-E5A68BA1040EQ36649749-518300D0-8A84-400B-AB5C-798AC9B4F724Q37372546-6C3C2E1B-17A8-4546-8BD4-CBA78262EA05Q38223526-C1B05C5E-B8E9-480E-AE13-8AF516B9CE86Q41204558-82F24B24-278A-4915-B467-CDA2823D7F46
P2860
Dose-response relationships for alendronate treatment in osteoporotic elderly women. Alendronate Elderly Osteoporosis Study Centers
description
article
@en
im Januar 1997 veröffentlichter wissenschaftlicher Artikel
@de
wetenschappelijk artikel
@nl
наукова стаття, опублікована в січні 1997
@uk
name
Dose-response relationships fo ...... rly Osteoporosis Study Centers
@en
Dose-response relationships fo ...... rly Osteoporosis Study Centers
@nl
type
label
Dose-response relationships fo ...... rly Osteoporosis Study Centers
@en
Dose-response relationships fo ...... rly Osteoporosis Study Centers
@nl
prefLabel
Dose-response relationships fo ...... rly Osteoporosis Study Centers
@en
Dose-response relationships fo ...... rly Osteoporosis Study Centers
@nl
P2093
P356
P1476
Dose-response relationships fo ...... rly Osteoporosis Study Centers
@en
P2093
Downs RW Jr
Polvino WJ
Weinstein RS
P304
P356
10.1210/JCEM.82.1.3682
P407
P577
1997-01-01T00:00:00Z